Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[LDL-apheresis: current status].

C Stefanutti1, A Vivenzio, G Lucani

  • 1Sezione di Plasmaferesi Terapeutica, Istituto di Terapia Medica Sistematica, Policlinico Umberto I, Università degli Studi di Roma La Sapienza, Roma, Italia. plasmaferesi@tin.it

La Clinica Terapeutica
|May 31, 2001
PubMed
Summary

LDL-apheresis effectively treats severe familial hypercholesterolemia in pediatric and adult patients. This advanced therapy improves metabolic function and prevents atherosclerotic complications, offering a safe and effective treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One year of surgical mask testing at the University of Bologna labs: Lessons learned from data analysis.

Separation and purification technology·2022
Same author

Corrigendum to: "MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma" [Biochim. Biophys. Acta, Gene Regul. Mech. 1861 (2018) 235-245].

Biochimica et biophysica acta. Gene regulatory mechanisms·2020
Same author

Corrigendum to "Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of breast surgeons (ANISC)" [Breast 2019 56-60].

Breast (Edinburgh, Scotland)·2019
Same author

Secondary breast angiosarcoma: A multicentre retrospective survey by the national Italian association of Breast Surgeons (ANISC).

Breast (Edinburgh, Scotland)·2019
Same author

Immune Response and Partial Protection against Heterologous Foot-and-Mouth Disease Virus Induced by Dendrimer Peptides in Cattle.

Journal of immunology research·2018
Same author

Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.

Journal of clinical apheresis·2018

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Medical Technology

Context:

  • Familial hypercholesterolemia (FH) is a severe genetic disorder leading to premature cardiovascular disease.
  • Current treatment strategies for severe FH, particularly in pediatric populations, require effective and safe interventions.
  • LDL-apheresis represents a significant therapeutic advancement for managing extreme lipid profiles.

Purpose:

  • To review the current state of LDL-apheresis for treating severe familial hypercholesterolemia.
  • To present clinical experience with LDL-apheresis in pediatric and adult FH patients.
  • To evaluate the efficacy and safety of various LDL-apheresis techniques (DALI, HELP, DSC).

Summary:

  • LDL-apheresis was applied to 11 pediatric patients, including a 3.5-year-old, demonstrating its applicability in very young individuals.

Related Experiment Videos

  • The treatment successfully improved metabolic abnormalities associated with FH.
  • LDL-apheresis effectively halted the progression of atherosclerotic disease and its complications in treated patients.

    • Impact:

    • LDL-apheresis is established as a highly effective and safe therapeutic approach for homozygous, heterozygous, and double heterozygous FH.
    • Early intervention with LDL-apheresis in pediatric patients can significantly alter the long-term prognosis of FH.
    • This therapy provides a critical treatment option for patients with severe hypercholesterolemia unresponsive to conventional management.